Sumitomo Dainippon Pharma Co., Ltd.
50 articles about Sumitomo Dainippon Pharma Co., Ltd.
-
Ulotaront failed to meet primary endpoints in two studies. The companies said high COVID-19 placebo effect “may have masked molecule’s therapeutic effect” and plan to discuss next steps with the FDA.
-
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America
4/3/2023
Sunovion Pharmaceuticals Inc., an indirect, wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sumitomo Pharma Oncology, Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.
-
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America
4/3/2023
Sumitovant Biopharma Ltd. announced that its parent company Sumitomo Pharma Co., Ltd. will combine its wholly owned U.S. subsidiaries to form Sumitomo Pharma America, Inc.
-
Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitomo Pharma Oncology, to Combine and Form Sumitomo Pharma America
4/3/2023
Sumitomo Pharma Oncology, Inc., a wholly owned subsidiary of Sumitomo Pharma Co. Ltd, announced that it will combine with affiliate companies Sumitomo Pharma America Holdings, Inc., Sumitovant Biopharma Ltd., Myovant Sciences, Inc., Urovant Sciences, Inc., Enzyvant Therapeutics, Inc., and Sunovion Pharmaceuticals Inc. to form Sumitomo Pharma America, Inc. effective July 1, 2023.
-
Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
10/24/2022
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., and Myovant Sciences announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.
-
Sumitovant Biopharma and Sumitomo Pharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
10/3/2022
Sumitovant Biopharma Ltd., in conjunction with parent company Sumitomo Pharma Co., Ltd., announced it has submitted a non-binding proposal to the Audit Committee of the Board of Directors of Myovant Sciences Ltd. offering to acquire all outstanding shares of Myovant not already owned by Sumitovant for $22.75 per share in cash.
-
Myovant Sciences formed a special committee of independent directors to assess Sumitovant Biopharma's offer after Sumitovant announced plans to acquire the company.
-
Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
10/2/2022
Myovant Sciences Ltd. confirmed that it has received a preliminary, non-binding proposal from Sumitovant Biopharma Ltd. and Sumitomo Pharma Co., Ltd. to acquire the remaining shares of the Company that Sumitovant does not currently hold, for a price of $22.75 per share in cash.
-
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
5/4/2022
Jazz Pharmaceuticals plc and Sumitomo Pharma Co., Ltd. announced that the companies have entered into an exclusive licensing agreement under which Jazz has acquired development and commercialization rights in the United States, Europe and other territories for Sumitomo Pharma's investigational DSP-0187.
-
Sumitomo Dainippon Pharma Oncology Provides Update on Phase 3 WIZARD 201G Study of Ombipepimut-S Emulsion (DSP-7888) in Patients with Recurrent or Progressive Glioblastoma
12/15/2021
Sumitomo Dainippon Pharma Oncology, Inc. announced that the Phase 3 WIZARD 201G study will terminate following its second interim analysis after determining there is a low probability of meeting the primary endpoint of overall survival at the final analysis.
-
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
-
Her career as a physician and scientist is guided by a combination of logic and creativity.
-
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma
11/3/2021
Sumitomo Dainippon Pharma Oncology, Inc. today announced that the first patient has been dosed in the Phase 1 dose expansion portion of the study evaluating the investigational agent TP-1287
-
Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Study of DSP-0390 in Patients with Recurrent High-Grade Glioma
10/21/2021
Sumitomo Dainippon Pharma Oncology, Inc. today announced the first patient has been dosed in a Phase 1 study evaluating its investigational agent DSP-0390, an emopamil-binding protein (EBP) inhibitor
-
Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration
9/30/2021
Sunovion Pharmaceuticals Inc.,its parent company Sumitomo Dainippon Pharma Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront, non-racemic ratio of amisulpride enantiomers, SEP-378614 and SEP-380135.
-
The companies said the collaboration recognizes a “great need for novel treatments in the area of neuropsychiatric medicine development.”
-
Experts are predicting a record-breaking rush of IPOs this fall as companies flood to the Nasdaq.
-
Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan
6/23/2021
POXEL SA, a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis, and Sumitomo Dainippon Pharma Co., Ltd., announced that a new drug application for TWYMEEG® Tablets 500mg3 : Imeglimin hydrochloride), for the treatment of type 2 diabetes, was approved in Japan on June 23.
-
Exscientia Announces Second Molecule Created Using AI From Sumitomo Dainippon Pharma Collaboration to Enter Phase 1 Clinical Trial
5/13/2021
Second clinical molecule from Exscientia collaboration with Sumitomo Dainippon Pharma to begin Phase 1 trials in United States.
-
Sumitomo Dainippon Pharma Oncology Presents New Data from Investigational Pipeline of Novel Cancer Therapeutics at AACR Virtual Annual Meeting I 2021
4/10/2021
Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on research and development for novel cancer therapeutics, presented new findings on a range of investigational agents from the company's pipeline at the American Association for Cancer Research Virtual Annual Meeting I, taking place April 10-15, 2021.